Guido Oelkers, Sobi CEO
March 21, 2023 06:39 AM EDTUpdated 12:23 PM
R&D

So­bi's PhI­II gout win sets up a po­ten­tial ri­val­ry with fu­ture Am­gen as­set

Amber Tong

Al­most three years af­ter Swedish Or­phan Biovit­rum — per­haps bet­ter known as So­bi — shelled out $100 mil­lion in cash to li­cense Se­lec­ta’s ex­per­i­men­tal drug for chron­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times